These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28483286)

  • 1. [Acute tubulo-interstitial nephritis due to RIVAROXABAN (XARELTO)].
    Dantec A; Virot JS; Filancia A; Angonin R; Nefti H
    Presse Med; 2017 May; 46(5):541-542. PubMed ID: 28483286
    [No Abstract]   [Full Text] [Related]  

  • 2. [New oral anticoagulants in patients with atrial fibrillation in a urban health center].
    Rodríguez Pérez L; Capilla Lozano F; Gallego Fuentes R; Buitrago F
    Med Clin (Barc); 2016 Mar; 146(6):280-1. PubMed ID: 26343157
    [No Abstract]   [Full Text] [Related]  

  • 3. A case of rivaroxaban-associated acute tubulointerstitial nephritis.
    Monahan RC; Suttorp MM; Gabreëls BATF
    Neth J Med; 2017 May; 75(4):169-171. PubMed ID: 28522776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of early initiation of rivaroxaban or dabigatran after thrombolysis in acute ischemic stroke.
    Ritzenthaler T; Derex L; Davenas C; Bnouhanna W; Farghali A; Mechtouff L; Cho TH; Nighoghossian N
    Rev Neurol (Paris); 2015 Sep; 171(8-9):613-5. PubMed ID: 25857461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban-Induced Acute Interstitial Nephritis: A Case Report.
    Zafar F; Iqbal AM; Mubarik A; Rojas M; Muddassir S
    Am J Case Rep; 2019 Nov; 20():1719-1722. PubMed ID: 31748498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban-induced hemorrhagic pericardial tamponade in end-stage renal disease.
    Rapista N; Sarkar S; Chaudhary R
    J Thromb Thrombolysis; 2020 Nov; 50(4):982-983. PubMed ID: 32495012
    [No Abstract]   [Full Text] [Related]  

  • 8. [Good efficacy and safety profile in clinical practice].
    MMW Fortschr Med; 2015 Nov; 157(20):66-7. PubMed ID: 26977521
    [No Abstract]   [Full Text] [Related]  

  • 9. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
    Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
    Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spontaneous, Life-Threatening Hemorrhagic Cardiac Tamponade Secondary to Rivaroxaban.
    Kham NM; Song M
    Am J Ther; 2016; 23(4):e1128-31. PubMed ID: 26035030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study.
    Engelberger RP; Noll G; Schmidt D; Alatri A; Frei B; Kaiser WE; Kucher N
    Eur J Intern Med; 2015 Sep; 26(7):508-14. PubMed ID: 25935131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Real life clinical management of nonvalvular atrial fibrillation: results from the Italian epidemiological survey eXperience on the use of rivaroxaban].
    Colonna P; Ammirati F;
    G Ital Cardiol (Rome); 2016 Nov; 17(11):932-939. PubMed ID: 27996999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Andexanet alfa-The first 150 days.
    Culbreth SE; Rimsans J; Sylvester K; Pallin DJ; Connors JM
    Am J Hematol; 2019 Jan; 94(1):E21-E24. PubMed ID: 30358896
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk Factors for Major Bleeding in Rivaroxaban Users With Atrial Fibrillation.
    Tamayo SG; Simeone JC; Nordstrom BL; Patel MR; Yuan Z; Sicignano NM; Peacock WF
    J Am Coll Cardiol; 2016 Sep; 68(10):1144-6. PubMed ID: 27585515
    [No Abstract]   [Full Text] [Related]  

  • 15. Early Rivaroxaban Use After Cardioembolic Stroke May Not Result in Hemorrhagic Transformation: A Prospective Magnetic Resonance Imaging Study.
    Gioia LC; Kate M; Sivakumar L; Hussain D; Kalashyan H; Buck B; Bussiere M; Jeerakathil T; Shuaib A; Emery D; Butcher K
    Stroke; 2016 Jul; 47(7):1917-9. PubMed ID: 27222524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pruritus and rivaroxaban].
    Aguilar-Shea AL; Gallardo-Mayo C
    Semergen; 2018; 44(4):e96-e97. PubMed ID: 29439912
    [No Abstract]   [Full Text] [Related]  

  • 17. Prolongation of prothrombin time in the presence of rivaroxaban: is this the only cause?
    Sagheer S; McRae S
    Intern Med J; 2017 Feb; 47(2):225-227. PubMed ID: 28201865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coagulation Test Interpretation in a Patient Taking Direct Oral Anticoagulant Therapy.
    Sholzberg M; Xu Y
    JAMA; 2018 Oct; 320(14):1485-1486. PubMed ID: 30242329
    [No Abstract]   [Full Text] [Related]  

  • 19. CHA
    Peacock WF; Tamayo S; Patel M; Sicignano N; Hopf KP; Yuan Z
    Ann Emerg Med; 2017 May; 69(5):541-550.e1. PubMed ID: 27913059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracranial subdural hematomas with elevated rivaroxaban concentration and subsequently detected spinal subdural hematoma: A case report.
    Yamaguchi Y; Koga M; Matsuki T; Hino T; Yokota C; Toyoda K
    Thromb Res; 2016 Jul; 143():127-9. PubMed ID: 27240110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.